Advances in inflammasome biology are helping researchers address key selectivity and safety challenges in drug development.

Heart failure with preserved ejection fraction (HFpEF), a chronic inflammatory condition, is a leading cause of morbidity and mortality globally. Obesity, diabetes, and hypertension are highly ...

Alzheimer’s disease (AD), affecting around 6.9 million people in the US, is ranked as the seventh leading cause of death and is the most common cause of dementia among older adults. AD begins with ...

ZyVersa reports IC 100's potential to inhibit Alzheimer's progression by targeting NLRP3 inflammasomes, enhancing Aβ degradation in preclinical studies. ZyVersa Therapeutics, Inc. announced promising ...

Eli Lilly buys Ventyx Biosciences for $1.2B, targeting oral NLRP3 inflammasome inhibitors to expand its immunology pipeline ...

Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...